A5030704800- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Immunotherapy and Immune Responses
- Cancer Cells and Metastasis
- Biosimilars and Bioanalytical Methods
- Neuropeptides and Animal Physiology
- Glycosylation and Glycoproteins Research
- Immune Cell Function and Interaction
- HER2/EGFR in Cancer Research
- Medical Imaging Techniques and Applications
Vrije Universiteit Brussel
2021-2024
Targeted radionuclide therapy (TRT) using targeting moieties labeled with α-particle–emitting radionuclides (α-TRT) is an intensely investigated treatment approach as the short range of α-particles allows effective local lesions and micrometastases. However, profound assessment immunomodulatory effect α-TRT lacking in literature. <b>Methods:</b> Using flow cytometry tumors, splenocyte restimulation, multiplex analysis blood serum, we studied immunologic responses ensuing from TRT antihuman...
Introduction T cell Ig and ITIM domain receptor (TIGIT) is a next-generation immune checkpoint predominantly expressed on activated cells NK cells, exhibiting an unfavorable prognostic association with various malignancies. Despite the emergence of multiple TIGIT-blocking agents entering clinical trials, only fraction patients responded positively to anti-TIGIT therapy. Consequently, urgent demand arises for noninvasive techniques quantify monitor TIGIT expression, facilitating patient...
Radiofluorination of single domain antibodies (sdAbs) via N-succinimidyl-4-[
Targeted radionuclide therapy (TRT) using probes labeled with Lutetium-177 (177Lu) represents a new and growing type of cancer therapy. We studied immunologic changes in response to TRT 177Lu anti-human CD20 camelid single domain antibodies (sdAb) B16-melanoma model transfected express human CD20, the target antigen, ovalbumin, surrogate tumor antigen. High-dose induced melanoma cell death, calreticulin exposure, ATP-release vitro. Melanoma-bearing mice received fractionated low high-dose...
Monoclonal antibodies that target the inhibitory immune checkpoint axis consisting of programmed cell death protein 1 (PD-1) and its ligand, PD-L1, have changed immune-oncology field.We identified K2, an anti-human PD-L1 single-domain antibody fragment, can enhance T activation tumor killing.In this study, potential different K2 formats as blocking medicines was evaluated using a gene-based delivery approach.We showed 2K2 3K2, bivalent trivalent format generated 12 GS (glycine-serine)...
Abstract Blockade of the immune checkpoint axis consisting programmed death-1 (PD-1) and its ligand PD-L1 alleviates functional inhibition tumor-infiltrating lymphoid cells yet weakly induces their expansion. Exogenous cytokines could further expand thus synergize with αPD-L1 therapy. However, systemic delivery most causes severe toxicity due to unspecific expansion in periphery. Here, we modelled local therapeutics cell-containing vitro melanoma tumors. Three-dimensional tumor models...
Lung cancer thrives in a complex multicellular tumor microenvironment (TME) that impacts growth, metastasis, response, and resistance to therapy. While orthotopic murine lung models can partly recapitulate this complexity, they do not resonate with high‐throughput immunotherapeutic drug screening assays. To address the current need for relevant easy‐to‐use models, protocol is established generate evaluate fully histocompatible human spheroids, generated by coculturing fibroblasts cells...
<title>Abstract</title> Background Radiofluorination of single domain antibodies (sdAbs) via <italic>N</italic>-succinimidyl-4-[<sup>18</sup>F]fluorobenzoate ([<sup>18</sup>F]SFB) has shown to be a promising strategy in the development sdAb-based PET tracers. While automation prosthetic group (PG) been successfully reported, no practical method for large scale sdAb labelling reported. Therefore, we optimized and automated PG production, enabling subsequently efficient manual conjugation...
Supplementary Figure from Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model
Supplementary Figure from Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model
<div>Abstract<p>Targeted radionuclide therapy (TRT) using probes labeled with Lutetium-177 (<sup>177</sup>Lu) represents a new and growing type of cancer therapy. We studied immunologic changes in response to TRT <sup>177</sup>Lu anti-human CD20 camelid single domain antibodies (sdAb) B16-melanoma model transfected express human CD20, the target antigen, ovalbumin, surrogate tumor antigen. High-dose induced melanoma cell death, calreticulin exposure,...
<div>Abstract<p>Targeted radionuclide therapy (TRT) using probes labeled with Lutetium-177 (<sup>177</sup>Lu) represents a new and growing type of cancer therapy. We studied immunologic changes in response to TRT <sup>177</sup>Lu anti-human CD20 camelid single domain antibodies (sdAb) B16-melanoma model transfected express human CD20, the target antigen, ovalbumin, surrogate tumor antigen. High-dose induced melanoma cell death, calreticulin exposure,...